2014 Fiscal Year Final Research Report
A novel strategy for heart failure by anti-aging
| Project/Area Number |
24591100
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OIKAWA Masayoshi 福島県立医科大学, 医学部, 助教 (30457775)
SUZUKI Satoshi 福島県立医科大学, 医学部, 助教 (60536944)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
ISHIGAMI Akihito 地方独立行政法人東京都健康長寿医療センター, 東京都健康長寿医療センター研究所, 研究部長 (50270658)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | SMP30 / doxorubcin / oxidative stress / signal transduction / heart failure |
|---|
| Outline of Final Research Achievements |
Doxorubicin was administerd to wild type mice, SMP30 knockout mice, and transgenic mice with cardiac specific overexpression of SMP30. We demonstrated that SMP30 has a cardio-protective role by anti-oxidative and anti-apoptotic effects in doxorubicin-induced cardiotoxicity. Anti-aging gene, SMP30, can be a new therapeutic target to prevent heart failure.
|
| Free Research Field |
循環器内科学
|
